The conversation we have most often.
A customer slides a printed list of medications across the counter. Lisinopril for blood pressure. Atorvastatin for cholesterol. Sertraline (Zoloft) for the panic attacks that started after retirement. Sometimes a fish-oil capsule, sometimes Eliquis, sometimes warfarin for a heart valve. "My doctor mentioned I could try cannabis. Will any of this be a problem?"
The honest answer: maybe yes, depending on the specific medication and the cannabis dose. The peer-reviewed research on cannabis-prescription interactions is real, and the size of the effect depends on dose, frequency, and which enzyme metabolizes the prescription. Some interactions are well-documented (warfarin is the textbook case). Others are theoretical but plausible. Almost all of them get caught in a five-minute conversation with your pharmacist, if you take the time to have it.
This page lays out the actual research, the five medication categories most likely to interact, and the specific script for the pharmacist conversation. We are a cannabis retailer, not a clinic. We will not tell you it is safe to combine. We will tell you what the studies show and where to take the question.
The pharmacist conversation is free, takes under five minutes, and does not require an appointment. It is the most underused safety tool in cannabis use.
Why cannabis can change how your medications work.
Most prescription drugs are broken down in your liver by a family of enzymes called cytochrome P450 (CYP450). Different drugs use different CYP isoforms. THC and CBD, the two major cannabinoids in everything on our shelf, can inhibit several of these enzymes. When an enzyme is inhibited, the drug it metabolizes hangs around in your bloodstream longer than expected, sometimes producing a stronger effect than the prescribed dose was intended to.
This is not a fringe finding. A 2024 systematic review in Frontiers in Pharmacology, "Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis," catalogued the cannabinoid-CYP interactions across the published literature.1 A 2023 clinical pharmacology study by Bansal et al. in Clinical Pharmacology & Therapeutics tested oral CBD and CBD+THC products in healthy adults and reported the largest CYP inhibition effect on CYP2C19, followed by CYP2C9, CYP3A, and CYP1A2 at clinically relevant exposures.2
The five CYP enzymes that matter most for cannabis-prescription interactions:
- CYP2C9. Inhibited by both THC and CBD at clinically meaningful doses. Metabolizes warfarin, phenytoin, ibuprofen, and a few others. (Naproxen is mostly glucuronidated, not CYP-mediated, so the cannabis interaction is smaller there.)
- CYP3A4. Inhibited primarily by CBD, particularly at higher doses. Metabolizes a huge slice of prescription drugs: statins (atorvastatin, simvastatin), some calcium channel blockers, certain immunosuppressants (tacrolimus, cyclosporine), some benzodiazepines, certain antifungals.
- CYP2C19. Inhibited by CBD primarily, with smaller contributions from THC at clinically relevant doses (per Bansal 2023, this was the most-affected enzyme tested). Metabolizes some SSRIs (citalopram, escitalopram), clopidogrel (Plavix), some proton pump inhibitors, and others.
- CYP1A2 and CYP2B6. Affected to a lesser degree, but worth flagging for olanzapine, clozapine, bupropion (Wellbutrin), and a handful of others.
This is the technical foundation. The next section translates it into the actual list of medications most likely to be a problem.
The five medication categories most likely to interact.
Based on the 2024 Frontiers in Pharmacology systematic review and the 2023 Bansal et al. cytochrome study, the highest-confidence interaction categories are:
1. Blood thinners (anticoagulants)
Warfarin (Coumadin, Jantoven) is the textbook cannabis interaction case. Both THC and CBD inhibit CYP2C9, which metabolizes warfarin. The result can be elevated INR (a measure of how thin the blood is) and increased bleeding risk. A 2022 case report in the Journal of Cannabis Research (Hill et al.) documents this interaction in detail.3
Newer direct-acting anticoagulants like apixaban (Eliquis), rivaroxaban (Xarelto), and dabigatran (Pradaxa) also have potential interactions, especially with high-dose CBD products via CYP3A4. The signal is smaller than with warfarin but is documented enough to warrant the pharmacist conversation.
If you take any blood thinner, do not start cannabis without telling your prescriber. This is the highest-priority category.
2. Antiseizure medications
Phenytoin (Dilantin), clobazam, and valproate all have documented interactions with cannabinoids. Phenytoin is metabolized by CYP2C9 (inhibited by cannabis). High-dose CBD specifically has been shown to elevate clobazam levels (this is most relevant for Epidiolex patients, where the interaction is so well-documented that the FDA-approved cannabis drug carries explicit dosing-adjustment guidance for clobazam co-administration).
Antiseizure medications have a narrow therapeutic window: too little and the seizures break through, too much and toxicity sets in. If you have a seizure disorder, talk to your neurologist before adding any cannabis product.
3. Antidepressants (especially SSRIs)
The Zoloft question is the single most common prescription-interaction question we field at the counter. Sertraline (Zoloft) is metabolized partially by CYP2C19 and CYP3A4. Both enzymes can be inhibited by cannabinoids. The realistic risk profile is additive sedation, possible mood effects, and theoretically elevated SSRI blood levels.
The same general framing applies to citalopram (Celexa) and escitalopram (Lexapro), which use CYP2C19. Fluoxetine (Prozac) is metabolized primarily by CYP2D6 (which cannabinoids inhibit less), so the theoretical interaction is smaller than for sertraline. Bupropion (Wellbutrin) uses CYP2B6 and has theoretical concerns.
The interaction is generally not catastrophic at low cannabis doses, but combining cannabis with any SSRI is the kind of decision the pharmacist conversation is built for.
4. Statins (cholesterol medications)
Atorvastatin (Lipitor), simvastatin (Zocor), and lovastatin (Mevacor) are metabolized by CYP3A4, which is inhibited by CBD especially. The result can be elevated statin blood levels and increased risk of statin side effects (muscle pain, liver effects). Pravastatin (Pravachol) and rosuvastatin (Crestor) are metabolized differently and have lower interaction risk.
If you take a statin and want to use a high-dose CBD product, ask your pharmacist about it specifically. Low-THC, low-CBD products are usually less of a concern.
5. Immunosuppressants and narrow-therapeutic-window drugs
Tacrolimus, cyclosporine, and everolimus are immunosuppressants used after transplants or for certain autoimmune conditions. They are metabolized by CYP3A4. Even small changes in blood levels can mean rejection or toxicity. Cannabinoid co-administration is documented to alter these drugs' levels.
If you are on an immunosuppressant, do not start cannabis without telling your transplant team or rheumatologist.
What about blood pressure medications?
Customers ask about this often, particularly those on lisinopril, losartan, amlodipine, or metoprolol. The metabolic interaction with cannabinoids is generally smaller than the categories above, but there is a separate concern worth flagging: cannabis itself acutely changes blood pressure and heart rate.
The 2024 study published in the Journal of the American Heart Association, which we covered in our low-dose THC piece, found that THC-predominant cannabis raised heart rate by about 16 to 17 beats per minute and mean arterial pressure by 5 to 7 mmHg acutely. For someone on blood pressure medication, this can mean the drug is fighting against the cannabis effect, or it can mean a combined hypotensive episode when standing up too quickly. The interaction is more "additive cardiovascular effect" than "altered drug metabolism."
The pharmacist conversation still applies. Bring the BP medication list.
The five-minute pharmacist conversation.
This is the actual script. Walk into your pharmacy, ask to speak to the pharmacist (not the technician), bring your medication list, and say:
"I am thinking about trying low-dose cannabis. Here is my current medication list. Can you check whether any of these are flagged for interactions with THC or CBD?"
That is the whole conversation. The pharmacist will pull up the drug interaction database in real time, scan your list, and tell you which medications, if any, have a documented interaction with cannabinoids. If something is flagged, ask what the practical implication is: "Should I avoid cannabis entirely, or just use the lowest dose, or talk to my prescriber first?"
Why the pharmacist over your primary-care doctor for this specific question:
- Pharmacists do this every day. Drug interaction screening is their core competency. Primary-care physicians cover an enormous breadth of conditions; pharmacists drill on interactions specifically.
- Real-time database access. The pharmacy software flags interactions on every prescription fill. The pharmacist can run the screen on your med list in under three minutes.
- No appointment, no co-pay. The consultation is included in the cost of being their customer. Walk in, ask.
- Current cannabinoid training. Pharmacy continuing education has been ahead of medical school continuing education on cannabis interactions for years.
This does not replace the broader doctor conversation about whether cannabis is right for your specific health profile. That conversation belongs with your primary-care physician or specialist. The pharmacist conversation is the narrow, specific "will this interact with what I am already taking" question.
What we tell first-time customers at the counter.
The framing we use across the counter, for any adult considering low-dose cannabis while on prescription medications:
- Bring your medication list to your pharmacist. Have the five-minute conversation. Do this first.
- If nothing is flagged and you decide to proceed, customers who describe positive experiences most often describe starting at the low end of cited dose ranges. The University of Michigan's National Poll on Healthy Aging documents 2.5mg per serving as the consensus comfort range for adults new to cannabis or returning after a long break. Pay attention to how your body responds during the first week.
- If something is flagged but the pharmacist says low-dose is acceptable, follow whatever guidance they give about timing or dose.
- If something is flagged as a hard no (warfarin, phenytoin, certain immunosuppressants), trust them. Do not buy.
- Tell your prescribing doctor at your next visit, regardless. The pharmacist conversation does not replace the doctor relationship.
Some customers leave that conversation with a pharmacist's go-ahead to try a low-dose product. Others leave with a clear "not until you talk to your prescriber first." Both outcomes are correct. We are not the ones deciding which one applies to you. The point of this piece is that the question is answerable, and the person who can answer it for free is sitting behind the pharmacy counter at your usual drug store.
What about CBD-only products?
This question comes up enough to warrant its own section. CBD is often marketed as "the safer cannabinoid" with the implication that interactions are less of a concern. The peer-reviewed research does not entirely support this framing.
CBD is actually a more potent CYP inhibitor than THC for several enzymes, particularly CYP3A4 and CYP2C19. The FDA-approved CBD drug Epidiolex (used for specific pediatric seizure disorders) carries explicit warnings and dose-adjustment guidance for several co-medications, precisely because of these interactions. At the high CBD doses used therapeutically (often hundreds of mg per day), the interactions can be clinically significant.
For typical recreational CBD doses (under 25mg per day), the interactions are smaller, but the same pharmacist conversation applies. CBD is not a free pass.
A note on what this page is, and isn't.
This is consumer education from a licensed Michigan adult-use cannabis retailer. It is not medical advice. The sources we have cited (Frontiers in Pharmacology systematic review, Clinical Pharmacology & Therapeutics primary research, peer-reviewed case reports, FDA materials) are public and peer-reviewed. Read them yourself. The interaction research is still maturing, and we will update this page as it does.
If you take prescription medications and are considering cannabis, the single most useful step is the pharmacist conversation. Bring your medication list. Ask the question. The answer is usually quick.
If anything in this piece raised a question we did not answer, walk into Standish or Au Gres any day from 9 to 9 and ask. We will not pretend to be your doctor. We will tell you what we know, point you at your pharmacist for the interaction screen, and let you decide.